目录
Review
- Progression of liver disease and associated risk of hepatocellular carcinoma
- The role of percutaneous hepatic perfusion (PHP) in the treatment of cholangiocarcinoma
- Role of temporary portosystemic surgical shunt during liver resection to prevent a post-resection small for size-like syndrome
- Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunctionassociated steatotic liver disease
Editorial
- Reflections and perspectives on adjuvant treatment in the setting of resected hepatocellular carcinoma
- Introduction to 2023 Chinese expert consensus on the whole-course management of hepatocellular carcinoma
- Introduction of Chinese expert consensus on neoadjuvant therapy for primary liver cancer (2023 edition)